SciClone Pharmaceuticals, Inc. now functions as a specialty biopharmaceutical enterprise, with its core commercial and development activities centered on the dynamic healthcare market of Greater China. The company concentrates on the acquisition, advancement, and marketing of critical treatments for significant health challenges, particularly within the fields of oncology and severe infections, including key products for hepatitis management and immune system modulation.